Inoviq Ltd (AU:IIQ) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inoviq Ltd has announced a breakthrough in ovarian cancer testing, with its EXO-OC blood test achieving over 94% accuracy in independent patient validation. This promising development could revolutionize early-stage ovarian cancer detection, crucially improving patient outcomes and survival rates. The company plans to optimize the test for commercial use and further clinical validation.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.